skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PharmaLogo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

​Drive commercial success

drive commerical success pharma intelligence

As a pharmaceutical company, you need to continually evaluate your disease strategy to discern gaps in your portfolio and decide whether to build or buy. Internal candidates need to be assessed against competitors’ pipelines, and assets suitable for expanding your portfolio identified. To do all this, the right data and analysis is essential.

How we can help

Our portfolio strategy solutions give you timely and accurate intelligence you can act on, including:

  • A wealth of expert insights gathered by our global team of more than 65 journalists and over 300 specialist analysts
  • The most up-to-date, comprehensive coverage of drugs, companies, epidemiology, diseases, strategy, and pricing and reimbursement trends
  • Sales forecasts for pipeline candidates and patient-based sales forecasts from surveys of more than 200 physicians per indication
  • Country-specific treatment algorithms and reimbursement scenarios
  • Comprehensive and timely market research reports to help you understand macro trends and synthesize key insights so the ‘big picture’ always informs your commercial decisions
  •  Our Ask-the-Analyst™ service that puts you in direct contact with our global analyst team
Contact us

Relevant products

video-thumb-sample

Datamonitor Healthcare: data analysis and insight

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

Key benefits:

  • Prioritize market opportunities
  • Identify unmet needs
  • Make informed decisions
More
video-thumb-sample

Pharmapremia: Benchmark better and optimize your drug development pipeline

Using a peer-reviewed methodology that provides robust, unbiased drug phase success rates and timeline metrics by treatment indication, Pharmapremia enables you to make strong, informed decisions about your drug development pipeline.

Key benefits:

  • Manage portfolio risks
  • Analyze success factors
  • Create meaningful benchmarks
More
video-thumb-sample

In Vivo: strategic insights for life sciences decision-makers

In Vivo offers comprehensive coverage of the global medical industry’s competitive landscape.

Key benefits:

  • Cutting edge thought leadership
  • Expert analysis
  • Hear from news makers
More

Pharma Intelligence latest insights

  • In Vivo

    You May Be Making These Drug Forecasting Mistakes

    By Alex Chiang + Adrian Watson 15 Jan 2019

    What are the top 10 most common drug forecasting errors, and how can these be avoided? Life sciences consulting firm, Trinity Partners, explores the ins and outs of forecasting.

    Topic Drug approval Drug review

    View article

  • Datamonitor Healthcare

    Clinical Breakthroughs in Urological Cancers can be a Double-Edged Sword as Payers are Forced to Act

    By Louisa Joseph 10 Jan 2019

    The three urological cancers are undergoing tremendous changes in treatment practices as a result of new product launches and indication expansions.

    Topic Cancer

    View white paper

  • In Vivo

    Clinical Trials In 2019: Is Biopharma Ready To Tackle The Iron Triangle of Time, Cost and Quality?

    By William Looney 10 Jan 2019

    The clinical trial embodies the hope and the hassle of biopharma’s mission to develop new drugs for patients. It is an endlessly imperfect process: C-suite calls for more efficiency and speed at lower cost has been the story for decades. But an In Vivo conversation with a leading expert on trial management pinpoints three key trends that suggest better days are ahead for this central pillar of the innovation imperative.

    Topic Clinical trials

    View article

  • Pharmapremia

    Cancer Treatment is HARD!

    07 Jan 2019

    Drug development – it’s an area rife with risk, but with great risk often comes great rewards. An area notoriously prone to failure is oncology, and nowhere is accurate risk assessment more critical. Developing Cancer Treatments is HARD! But is everyone bad at it? is a view into this failure-prone area from Pharmapremia.

    Topic Cancer

    View infographic

  • Datamonitor Healthcare

    Neuropathic Pain Market and Forecast Analysis to 2026

    By Nicola Sawalhi-Leckenby 07 Jan 2019

    Big changes are coming to the neuropathic pain market – are you prepared? Take a look at the projected neuropathic pain drug sales for the US, Japan, and five EU nations with the latest infographic from Datamonitor Healthcare. This snapshot view of the future of the neuropathic pain market is packed with data from the full Datamonitor Healthcare Neuropathic Pain Disease Coverage report.

    View infographic

  • In Vivo

    Medical Aesthetics: A Untapped Pharma Market With Incoming Competition

    By Mandy Jackson 05 Dec 2018

    Medical aesthetics is a unique biopharmaceutical niche that may scare off companies due to the consumer marketing and doctor relationship-building skills needed to compete in this market, but the potential for growth keeps major players engaged and searching for new technology.

    Topic BioPharmaceutical

    View article

  • Datamonitor Healthcare

    Gene Therapy: A Paradigm Shift in Medicine

    By Amanda Micklus 30 Nov 2018

    The following analysis reviews several aspects of the gene therapy market. The history of gene therapy is briefly discussed, alongside a look at the trend in the volume of candidates in development over the past 20+ years, and how the regulatory landscape in the US and EU has recently adapted to help move the field forward. A deep dive into the pipeline with  breakdowns by delivery method and therapy area is provided, as are the key companies involved and the major partnership deals that have made gene therapy a hot commodity. Manufacturing, pricing, and reimbursement issues are also addressed.

    Topic Cell and gene therapy

    View white paper

  • Biomedtracker, Datamonitor Healthcare

    December 2018 National Influenza Week

    29 Nov 2018

    3 – 9 December is National Influenza Vaccination Week, a national awareness week focused on highlighting the importance of influenza vaccination. In this free KOL Insight Interview excerpt from Datamonitor Healthcare, read what key opinion leaders from the UK and US in Infectious Diseases have to say about current efforts to combat influenza with seasonal influenza vaccines:

    Topic Influenza virus Infectious diseases

    Single report

  • Datamonitor Healthcare

    World AIDS Day 2018 GlaxoSmithKline report

    29 Nov 2018

    PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.

    Topic Diseases Drug development landscape Drug review

    Single report

  • Datamonitor Healthcare

    Depression Disease Market and Forecast Analysis 2024

    24 Oct 2018

    Informa Pharma Intelligence is marking Depression Awareness Month with a free download of Depression Disease Market and Forecast Analysis 2024. Download your free extract from this vital report and tap into the exclusive data and insights into the depression market available only from the experts at Datamonitor Healthcare, part of the Informa Pharma Intelligence suite of tools.

    Topic Drug development landscape

    Single report

  • Datamonitor Healthcare

    Better Heart Health Whitepaper

    22 Oct 2018

    In recognition of World Heart Day, September 29, 2018, Informa Pharma Intelligence would like to invite you to download our latest whitepaper, Better Heart Health with Mobile Apps? The Impact of Mobile Apps on Coronary Heart Disease in the US. This exploration into the results of a recent analysis of the US Behavioral Risk Factor Surveillance System (BRFSS), coupled with an analysis of several health apps targeting coronary heart disease (CHD) and other heart disease factors, is available to you now – for free.

    View white paper

  • In Vivo

    Broader Capabilities Keep Consort On Top At Device End Of Drug Delivery

    By Ashley Yeo 06 Sep 2018

    Drug delivery technology specialist Consort Medical has capitalized on device respiratory expertise for 50 years, but a renewed focus on strategic expansion has seen it make an IP play, move into the pharma side and target other delivery formats for global pharma industry customers. Its enhanced capabilities will keep rivals on their toes.

    Topic Drug review Drug approval

    View article

  • Datamonitor Healthcare

    Meningococcal Vaccines Forecast Infographic

    By Karolina Kujawa 28 Aug 2018

    Over 1.2 million cases of bacterial meningitis are estimated to occur worldwide each year. If not treated promptly, up to half of those cases will be fatal. This infographic from Datamonitor Healthcare provides a snapshot of the meningococcal vaccines market in the US and five major EU markets. What does the meningococcal vaccines market have in store and how will it affect your business? Download now.

    Topic Vaccines

    View infographic

  • Datamonitor Healthcare

    Epidiolex and Epilepsy - big changes for medical marijuana

    By Stephanie Yip 28 Aug 2018

    With the FDA’s landmark approval of Epidiolex, a cannabidiol used to treat rare, severe pediatric epilepsies, the only obstacle to the legal sale of the drug is DEA reclassification of cannabidiol (CBD). With reclassification likely in the next 90 days, what does it mean for the epilepsy market, as well as the wider market for CBD?

    Topic Drug approval

    View white paper

  • Datamonitor Healthcare

    Japan Pharma Outlook 2027 Report Extract

    27 Aug 2018

    Download your complimentary Japan Pharma Outlook 2027 report extract. The 16-page excerpt includes highlights from the full report, which is available to subscribers of Datamonitor Healthcare, and available to purchase on our Report Store. Discover now the complex challenges and opportunities facing Japan Pharma.

    Single report

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now